Silence Therapeutics PLC (SLN) Financials
$13.62
As on 09-Sep-2026 13:36EDT
Market cap
$907 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
23.9
Div. Yield
0 %
Income Statement ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
0.61
|
0.56
|
43.26
|
25.38
|
17.65
|
12.42
|
|||||
|
Cost of Revenue
|
0.30
|
0.22
|
11.81
|
10.32
|
10.97
|
7.46
|
|||||
|
Gross Profit
|
0.31
|
0.34
|
31.45
|
15.06
|
6.68
|
4.96
|
|||||
|
Operating Expenses
|
67.15
|
90.10
|
94.77
|
64.66
|
56.44
|
50.77
|
|||||
|
Operating Profit (EBIT)
|
-66.84
|
-89.75
|
-63.32
|
-49.60
|
-49.76
|
-45.81
|
|||||
|
Other Income
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Profit before Tax
|
-59.95
|
-88.60
|
-44.46
|
-50.31
|
-40.47
|
-45.86
|
|||||
|
Provision for Tax
|
0.00
|
0.01
|
0.85
|
-7.04
|
0.56
|
-6.45
|
|||||
|
Profit after Tax (Net Income)
|
-59.95
|
-88.61
|
-45.31
|
-43.27
|
-41.03
|
-39.41
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
--
|
--
|
--
|
--
|
-40.49
|
-39.41
|
Liabilities ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
38.47
|
62.30
|
107.05
|
21.99
|
22.07
|
8.53
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
55.23
|
55.53
|
41.37
|
59.45
|
63.49
|
72.50
|
|||||
|
Current Liabilities
|
12.71
|
13.61
|
13.44
|
17.68
|
21.94
|
15.17
|
|||||
|
Total Liabilities
|
119.13
|
131.44
|
161.85
|
94.53
|
107.50
|
96.19
|
Assets ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
12.13
|
12.78
|
12.20
|
12.90
|
10.81
|
9.86
|
|||||
|
Current Assets
|
94.28
|
118.66
|
149.66
|
81.63
|
96.69
|
86.33
|
|||||
|
Total Assets
|
119.13
|
131.44
|
161.85
|
119.45
|
107.50
|
96.19
|
|||||
|
Total Debt*
|
0.11
|
0.16
|
0.09
|
0.27
|
0.45
|
0.14
|
|||||
|
Net Current Assets
|
81.57
|
105.05
|
170.54
|
63.25
|
74.74
|
71.17
|
Cashflow ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-62.27
|
-54.05
|
-39.35
|
-57.04
|
9.19
|
|||||
|
Cash Flow from Investing Activities
|
--
|
-47.99
|
-17.55
|
16.43
|
-20.50
|
11.71
|
|||||
|
Cash from Financing Activities
|
--
|
0.02
|
113.54
|
25.16
|
52.58
|
41.45
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
--
|
--
|
Financials Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-3.81
|
-5.63
|
-2.91
|
-3.28
|
-3.43
|
-1.33
|
|||||
|
Cash EPS ($)
|
--
|
-5.59
|
-2.88
|
-3.24
|
-3.39
|
-1.31
|
|||||
|
Adjusted Book Value ($)
|
--
|
3.96
|
6.88
|
1.67
|
1.84
|
0.29
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
-3.96
|
-3.48
|
-2.98
|
-4.76
|
0.31
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
-3.96
|
-3.49
|
-2.98
|
-4.81
|
0.25
|
Profitability Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
-104.49
|
-70.02
|
-193.22
|
-263.19
|
-436.36
|
|||||
|
ROE (%)
|
-118.98
|
-104.65
|
-70.22
|
-196.38
|
-268.20
|
-448.22
|
|||||
|
ROA (%)
|
-40.08
|
-60.43
|
-35.35
|
-42.83
|
-40.29
|
-43.27
|
|||||
|
EBIT Margin (%)
|
-9,892.63
|
-15,849.91
|
-114.62
|
-198.13
|
-228.99
|
-369.30
|
|||||
|
Net Margin (%)
|
-9,759.23
|
-15,851.88
|
-104.74
|
-170.51
|
-232.44
|
-317.44
|
|||||
|
Cash Profit Margin (%)
|
-0.02
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-97.63
|
-0.99
|
0.70
|
0.44
|
0.42
|
1.27
|
|||||
|
EBIT Growth (%)
|
26.29
|
-78.70
|
1.38
|
-24.37
|
11.83
|
-27.27
|
|||||
|
Net Profit Growth (%)
|
31.30
|
-95.57
|
-4.72
|
-5.45
|
-4.12
|
-21.09
|
|||||
|
EPS Growth (%)
|
31.24
|
-0.93
|
0.11
|
0.04
|
-1.58
|
-0.18
|
|||||
|
Book Value Growth (%)
|
-59.14
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
-1.08
|
-2.36
|
-5.30
|
-4.45
|
-17.97
|
|||||
|
Price / Book Value
|
23.89
|
1.54
|
1.00
|
10.43
|
8.28
|
83.08
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
-5.78
|
-0.12
|
0.22
|
-3.52
|
-2.80
|
-13.98
|
|||||
|
Close Price ($)
|
10.98
|
6.08
|
6.88
|
17.37
|
15.25
|
23.89
|
|||||
|
High Price ($)
|
11.05
|
8.08
|
27.72
|
18.95
|
24.66
|
35.00
|
|||||
|
Low Price ($)
|
4.19
|
1.97
|
5.81
|
4.55
|
7.80
|
20.50
|
|||||
|
Market Cap ($ Cr)
|
906.83
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
--
|
0.00
|
0.00
|
0.01
|
0.02
|
0.02
|
|||||
|
Short term debt to equity ratio
|
0.00
|
0.00
|
0.00
|
0.01
|
0.02
|
0.02
|
|||||
|
Current Ratio
|
7.42
|
8.72
|
11.14
|
4.62
|
4.41
|
5.69
|
|||||
|
Quick Ratio
|
7.42
|
--
|
--
|
5.67
|
5.15
|
5.69
|
|||||
|
Interest Coverage
|
--
|
--
|
--
|
-1,478.71
|
-860.09
|
-5,731.00
|
Operating Efficiency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
1,512.64
|
4,403.22
|
1.79
|
74.78
|
5.18
|
2.67
|
|||||
|
Asset Turnover
|
0.00
|
0.00
|
0.34
|
0.25
|
0.17
|
0.14
|
|||||
|
Receivable days
|
--
|
8,295.02
|
83.38
|
143.14
|
12.89
|
435.96
|
|||||
|
Inventory Days
|
--
|
--
|
-575.40
|
-620.05
|
-273.35
|
36.54
|
|||||
|
Payable days
|
--
|
6,253.37
|
86.63
|
103.29
|
120.66
|
155.53
|
|||||
|
Cash Conversion Cycle
|
--
|
--
|
-578.65
|
-580.20
|
-381.11
|
316.97
|